item management s discussion and analysis of financial condition and results of operations 
the following discussion and analysis by management is provided to identify certain significant factors which affected the company s financial position and operating results during the periods included in the accompanying financial statements 
overview and risk factors the company is a biopharmaceutical company engaged primarily in the research and development of therapeutic products for the treatment of selected cancers and cancer related disorders 
the products under development include cancer therapeutics  cancer vaccines and inhibitors of angiogenesis 
since its inception in april  the company has devoted substantially all of its efforts and resources to research and development conducted on its own behalf and through collaborations with corporate partners and academic research and clinical institutions 
the company has generated a cumulative net loss of approximately  for the period from its inception to december  the company expects to incur significant additional operating losses over each of the next several years 
the major sources of the company s working capital have been the proceeds from the public and private sale of equity securities  the sale of the ida bonds by the nyida the proceeds of which have been used for the acquisition  construction and installation of the company s research and development facility in new york city  license fees and contract research and development fees and royalties from collaborative partners and interest earned on these funds 
substantially all of the company s products are in various stages of development  clinical studies or research 
substantially all the company s revenues were generated from license and research arrangements with collaborative partners 
the company s revenues under its research and license agreements with corporate sponsors have fluctuated and are expected to fluctuate significantly from period to period 
similarly  the company s results of operations have fluctuated and are expected to fluctuate significantly from period to period 
these variations have been  and are expected to be  based primarily on the timing of entering into supported research and license agreements  the status of the company s various products  the timing and level of revenues from sales by its partner in diagnostics  abbott  of products bearing the company s technology  the addition or termination of research programs or funding support  performance by the company s corporate collaborators of their funding and marketing obligations  the achievement of specified research or development milestones  including those relating to the company s amended license agreement with merck  and variations in the level of expenditures for the company s proprietary products during any given period 
the company s products will require substantial additional development and clinical testing and investment prior to commercialization 
to achieve profitable operations  the company  alone or with others  must successfully develop  introduce and market its products 
no assurance can be given that any of the company s product development efforts will be successfully completed  that required regulatory approvals can be obtained or that any products  if developed  will be successfully manufactured or marketed or achieve customer acceptance 
results of operations years ended december  and december  revenues revenues for the years ended december  and were  and  respectively  an increase of  revenue for the year ended december  consisted of i  in research support from the company s partnership with american home products in infectious disease vaccines  ii  in milestone payments and  in research and support payments from the company s amended license agreement with merck  and iii  in milestone payments and  in royalty revenue from the company s strategic alliance with abbott in diagnostics 
revenues for the year ended december  consisted of i  in research support from the company s partnership with the wyeth lederle vaccine and pediatrics division of american home in infectious disease vaccines  ii  in royalty revenue from the abbott alliance  and iii  in license fees from the company s cross licensing agreement with immunex for novel hematopoietic growth factors 
increased revenues for the year ended december  were primarily attributable to the company s having achieved development milestones under the company s amended license agreement with merck and the company s strategic license with abbott 
operating  research and development expenses total operating expenses for the years ended december  and were  and  respectively  an increase of  or 
research and development expenses for the years ended december  and were  and  respectively  an increase of  or 
such amounts for the years ended december  and december  represented and  respectively  of total operating expenses 
the increase in research and development expenses for the year ended december  was partly attributable to a one time  non cash compensation expense recorded in connection with the extension of the term of an officer s warrant to purchase  shares of common stock 
the increase is also attributable to costs associated with additional staffing  contract manufacturing and testing  and expenditures in the functional areas of product development  manufacturing and clinical and regulatory affairs to support the company s lead therapeutic product candidate  c  as well as travel related expenses to pursue strategic partnerships for c and other product candidates 
the remaining increase reflects growth in the area of discovery research for future product candidates 
general and administrative expenses general and administrative expenses include administrative personnel costs  costs incurred in connection with pursuing arrangements with corporate partners and technology licensors  and expenses associated with applying for patent protection for the company s technology and products 
such expenses for the years ended december  and were  and  respectively  an increase of  or 
the increase in general and administrative expenses primarily reflects i  non cash compensation expense recorded in connection with an option grant to an officer of the company and ii additional support staffing for the expanding research  clinical  development and manufacturing efforts of the company  particularly with respect to c the company expects general and administrative expenses to increase in future periods to support planned increases in research and development 
interest and other income and expenses interest and other income was  for the year ended december  compared to  for the year ended december   an increase of  or 
the increase was primarily attributable to the increased interest income earned from higher cash balances in the company s investment portfolio resulting from the proceeds received from a public offering of common stock completed in march and a private placement of series a preferred stock completed in december interest expense was  and  for the years ended december  and  respectively  a decrease of  or 
interest expense for both periods primarily included interest on two then outstanding ida bonds with an aggregate principal amount of   of which was repaid in december and interest recorded on the liability to pharmacia and upjohn inc pharmacia  for the reacquisition of the worldwide rights to il m as well as clinical material manufactured and supplied by pharmacia to the company 
the decrease was primarily attributable to the may exchange of debt for common stock with the oracle group and a company director 
net losses the company had net losses to common stockholders of  or per share for the year ended december   compared with  or per share for the year ended december  the year ended december  included a  or per share extraordinary loss on early extinguishment of debt 
this extraordinary loss resulted from the issuance of common stock in lieu of cash repayment of a  loan due the oracle group and a  long term note owed to a company director 
the decrease in the per share net loss to common stockholders is due primarily to the increased number of shares of common stock outstanding as a result of the march public offering of common stock 
years ended december  and december  revenues revenues for the years ended december  and were  and  respectively  a decrease of  revenues for consisted of i  in research support from the company s corporate partnership with the wyeth lederle vaccine and pediatrics division of american home  ii royalty revenue of  from the company s strategic alliance with abbott  iii and  in license fees from the company s cross licensing agreement with immunex 
revenues for consisted of i  in research support from the company s corporate partnership with the wyeth lederle vaccine and pediatrics division of american home  and ii contract research fees of  from the company s strategic alliance with abbott 
operating  research and development expenses total operating expenses for the years ended december  and december  were  and  respectively  an increase of  or 
research and development expenses for the years ended december  and december  were  and  respectively  an increase of  or 
such amounts for the years ended december  and december  represented and  respectively  of total operating expenses 
the increase in research and development expenses is primarily attributable to costs incurred for c  the company s lead therapeutic product candidate 
this includes additional staffing and expenditures in the functional areas of product development  manufacturing and clinical and regulatory affairs to support the manufacture of c for human clinical trials and travel related expenses to pursue strategic partnerships for c and other product candidates 
the remaining increase reflects growth in the area of discovery research for future product candidates 
general and administrative expenses general and administrative expenses include administrative personnel costs  costs incurred in connection with pursuing arrangements with corporate partners and technology licensors  and expenses associated with applying for patent protection for the company s technology and products 
such expenses for the year ended december  were  compared to  for the year ended december   an increase of  or 
the increase primarily reflects additional staffing to support the expanding research  clinical  development and manufacturing efforts of the company  particularly with its lead therapeutic product candidate  c the company expects general and administrative expenses to increase in future years to support planned increases in research and development 
interest and other income and expenses interest and other income was  for the year ended december  as compared to  for the year ended december   a decrease of  or 
other income for the year ended december  included the company s sale of the remaining one half of its shares of capital stock of cadus pharmaceutical corporation  a company it assisted in founding in  for  to high river  lp 
the greater interest income earned during the year ended december  reflects the company s improved cash position from the november and february public sales of shares of its common stock 
interest expense was  and  for the years ended december  and december   respectively  a decrease of  or 
such expense for both years primarily included interest on two then outstanding ida bonds with an aggregate principal amount of   of which was repaid in december  interest recorded on the liability to pharmacia for the reacquisition of the worldwide rights to il m and the contract manufacture of clinical material  and interest accrued and the amortization of the non cash debt discount recorded in connection with the company s august financing with the oracle group 
net losses the company had net losses to common stockholders of  or per share  and  or per share  for the years ended december  and december   respectively 
the net loss to common stockholders for the year ended december  included a  or per share extraordinary loss on early extinguishment of debt through the may issuance of common stock in lieu of cash repayment of a  loan due the oracle group and a  long term note owed to a company director 
liquidity and capital resources at december   the company s principal sources of liquidity consisted of cash and cash equivalents and securities available for sale of approximately  the company has financed its operations since inception primarily through the public and private sales of equity securities  the sale of the ida bonds through the nyida  license fees and contract research and development fees and royalties received under agreements with collaborative partners and interest earned on these funds 
since inception  public and private sales of equity securities have raised approximately  in net proceeds  including approximately  raised in a public offering of  shares of common stock in march and approximately  raised in a private placement of  series a preferred shares in december the sale of the ida bonds in each of  and raised an aggregate of  the proceeds of which have been used for the acquisition  construction and installation of the company s research and development facility in new york city  and of which  is currently outstanding 
since inception  the company has earned approximately  from license fees  contract research and development fees and royalties from collaborative partners  including approximately  received in since inception the company has earned approximately  in interest income  including approximately  in the company has obligations under various capital leases for certain laboratory  office and computer equipment and also certain building improvements primarily under a december financing agreement with finova technology finance  inc finova 
the agreement allows the company to finance the lease of equipment and make certain building and leasehold improvements to existing facilities involving amounts aggregating approximately  as of december   the company had entered into six individual leases aggregating a total cost of  each lease has a fair market value purchase option at the expiration of a month term 
pursuant to the agreement  the company issued to finova a warrant expiring december  to purchase  shares of common stock at an exercise price of per share 
the company recorded a non cash debt discount of approximately  in connection with this financing  which discount is being amortized over the month term of the first lease 
the financing agreement with finova expired in december and the company did not utilize the full  under the agreement 
the company anticipates that it will enter into a new financing agreement with finova during the second quarter of aggregating approximately  however  no assurance can be given that such agreement will be consummated 
the company has expended and will continue to expend in the future substantial funds to continue the research and development of its products  conduct pre clinical and clinical trials  establish clinical scale and commercial scale manufacturing in its own facilities or in the facilities of others  and market its products 
the company has entered into preliminary discussions with several major pharmaceutical companies regarding various alternatives concerning the funding of research and development for certain of its products 
no assurance can be given that the company will be successful in consummating any such alternatives 
these discussions have included potential significant strategic alliances for the development and commercialization of the company s lead product candidate  c such strategic alliances could include up front license fees plus milestone fees and revenue sharing 
there can be no assurance that the company will be successful in achieving such alliances  nor can the company predict the amount of funds which might be available to it if it entered into such alliances or the time at which such funds would be made available 
in january  the company completed the construction and commissioning of a new  square foot process development center at its somerville  new jersey facility at a cost of approximately  the company has also taken steps to complete a formal design concept for large scale manufacturing at this facility 
if the company adapts this facility to large scale manufacturing or does so at another location  it will incur substantial additional costs 
the lease on the company s new york city facility expires in march the company is currently in discussions regarding the extension of the lease and is considering other alternatives  such as relocating its executive offices and laboratories to a new facility 
were the company to relocate its executive offices and laboratories  it would incur substantial additional costs 
the ida bond issued in the ida bond in the outstanding principal amount of  becomes due in if the lease on the company s new york city facility is terminated  the ida bond provides that it will become due days prior to such termination 
interest payable on the ida bond will aggregate approximately  during the company has granted the nyida a security interest in substantially all facility equipment located in the new york facility to secure the obligations of the company to the nyida under the ida bond 
in december  the company paid off the outstanding principal on the ida bond issued in in the aggregate principal amount of  plus accrued and unpaid interest thereon 
the holders of the series a preferred shares are entitled to receive cumulative dividends at an annual rate of per share 
dividends accrue as of the issuance date of the series a preferred shares and are payable on the outstanding series a preferred shares in cash on december of each year beginning december  or at the time of conversion or redemption of the series a preferred shares on which the dividend is to be paid  whichever is sooner 
accrued dividends were  plus the incremental yield on the conversion discount of  at december  total capital expenditures made during the year ended december  were  of the total capital expenditures made during the year ended december    has been reimbursed in accordance with the terms of the finova agreement discussed above which provides for improvements and equipping of the company s manufacturing facility in new jersey 
the balance of capital additions was for equipment and computer related purchases for both the new jersey facility and the corporate office and research laboratories in new york 
the company anticipates that its existing capital resources  including the on going research support of its corporate partners  should enable it to maintain its current and planned operations through the end of the year however  the receipt of such ongoing research support is subject to attaining research and development milestones  certain of which have not yet been achieved 
there can be no assurance that the company will achieve these milestones 
the company s future working capital and capital requirements will depend upon numerous factors  including the progress of the company s research and development programs  pre clinical testing and clinical trials  the company s corporate partners fulfilling their obligations to the company  the timing and cost of seeking regulatory approvals  the cost of manufacturing scale up and effective commercialization activities and arrangements  the level of resources that the company devotes to the development of marketing and sales capabilities  the costs involved in filing  prosecuting and enforcing patent claims  technological advances  the status of competitors and the ability of the company to maintain existing and establish new collaborative arrangements with other companies to provide funding to the company to support these activities 
in order to fund its capital needs after the end of the year  the company will require significant levels of additional capital and intends to raise the capital through additional arrangements with corporate partners  equity or debt financings or from other sources 
there is no assurance the company will be successful in consummating any such arrangements 
if adequate funds are not available  the company may be required to significantly curtail its planned operations 
uncertainties associated with the length and expense of pre clinical and clinical testing of any of the company s products could greatly increase the cost of development of such product and affect the timing of anticipated revenues from product sales  and failure by the company to obtain regulatory approval for any product will preclude its commercialization 
in addition  the failure by the company to obtain patent protection for its products may make certain of its products commercially unattractive 
at december   the company had net operating loss carryforwards for federal income tax purposes of approximately  which expire at various dates from through at december  the company had research credit carryforwards of approximately  which expire at various dates between years and pursuant to section of the internal revenue code of  as amended  the annual utilization of the company s net operating loss and research credit carryforwards may be limited if the company experiences a change in ownership of more than percentage points within a three year period 
since  the company experienced two ownership changes 
accordingly  the company is significantly limited in utilizing its tax net operating loss carryforwards arising before such ownership changes to offset future federal taxable income 
similarly  the company is significantly restricted in using its research credit carryforwards arising before such ownership changes to offset future federal income tax expense 
other items the company is evaluating the risks and costs associated with the year conversion 
the company intends to communicate with those organizations with which it does business to ensure that year issues will be resolved in a timely manner 
if necessary modifications and conversions by those with which the company does business are not completed timely  the year conversion issue may have a material adverse effect on the company s consolidated financial position and results of operations 
based on the company s ongoing evaluation  management does not currently believe that the costs to achieve year compliance will be material to the company s financial position or results of operations 
item a 
quantitative and qualitative disclosures about market risk not applicable 

